2024-511151-18-01RecruitingPhase 1
Takeda Brentuximab; Molecular Imaging of Zirconium-89-labeled Brentuximab as a Tool to Investigate brentuximab biodistribution in CD30-positive Lymphoma
Source: EU CTIS (euclinicaltrials.eu) · Last updated 25 Nov 2024 · Not updated for over 12 months - ask the site whether it is still open
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 16 Oct 2024
- Start date
- 2 Jan 2025
- Lead sponsor
- Universitair Medisch Centrum Groningen
- Diseases
- Diffuse large B-cell lymphoma
- EU CT number
- 2024-511151-18-01
- EudraCT number
- 2021-005950-27
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 20
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Universitair Medisch Centrum Groningen Coordinator of this site? Confirm its status | Groningen | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.